Inclusion Criteria:  According to the Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke 2018, the patient is clinically diagnosed as acute ischemic stroke; ≥ 18 years of age, regardless of gender; Patients who have received or are scheduled to receive intravenous thrombolysis with alteplase, that is, receiving thrombolysis with alteplase within 4.5 hours of onset of ischemic stroke; Intravenous antiplatelet therapy is acceptable within 12 hours of receiving intravenous thrombolysis; NIHSS score: 4 ≤ screening period/baseline NIHSS score ≤ 25; Be able to engage in daily life independently before the onset of this ischemic stroke (mRS score: 0-1 point); The subject or his/her guardian participates voluntarily and signs the ICF.  Exclusion Criteria:  Combined with atrial fibrillation or clear evidence of cardiogenic embolism (e.g., known left atrial/left ventricular mural thrombosis, etc.); CT suggests large-area anterior circulation infarction (ASPECT score is < 6 points or infarction volume is ≥ 70 mL or infarction area is > 1/3 of the middle cerebral artery blood supply area); Significant head trauma or stroke within 3 months prior to screening; Previous history of intracranial hemorrhage (e.g., subarachnoid hemorrhage, and intracerebral hemorrhage); Previous intracranial tumor, arteriovenous malformation or aneurysm; Intracranial or spinal surgery and biopsy within 3 months prior to screening; Prolonged or traumatic cardiopulmonary resuscitation (> 2 min), delivery within the past 10 days or recent puncture of a non-compression vessel (e.g., subclavian vein or jugular vein); Presence of active internal hemorrhage (e.g., gastrointestinal, urinary tract or retinal hemorrhage, etc.); Hemorrhagic tendency (including but not limited to): platelet count < 100 × 109/L during screening; heparin treatment within the last 48 hours and APTT exceeding the upper limit of laboratory normal value; oral administration of warfarin at the time of screening, INR > 1.7; oral administration of new anticoagulants; and using direct thrombin or factor Xa inhibitors; Hypertension is not controlled after active antihypertensive therapy: systolic blood pressure is ≥ 180 mmHg or diastolic blood pressure is ≥ 100 mmHg; Blood glucose concentration is < 50 mg/dL (2.8 mmol/L) or > 400 mg/dL (22.2 mmol/L); Severe liver damage, including liver failure, cirrhosis, portal hypertension (esophageal varices), and active hepatitis; Serious renal insufficiency (creatinine clearance rate is < 30 mL/min); Currently undergoing renal dialysis; Aortic dissection; Major surgery or serious trauma within 30 days prior to screening; Gastrointestinal or urethral hemorrhage within 30 days prior to screening; History of acute myocardial infarction within 3 months prior to screening; It is known at the time of screening that subjects plan to undergo coronary, carotid or peripheral arterial revascularization during the trial; Female subjects who are serum pregnancy test positive, pregnant/lactating women, or women of childbearing potential who plan to have a pregnancy during the 12-month period, or women of childbearing potential or male subjects who are unwilling to take appropriate contraceptive measures during the trial; Users who are known to be allergic or contraindicated to the investigational product; Life expectancy of < 6 months due to any advanced disease; Patients who have participated in drug or device trials within one month; Patients with poor peripheral venous filling who cannot establish two standard peripheral venous lines; Stroke accompanied by seizures; Other conditions that the investigator considers inappropriate for participation in the clinical study, such as inability to understand and/or follow the study procedures and/or follow-up due to mental disorders, cognitive or emotional disorders.